Vimarsana
Biggest News Aggregation in the World

Page 20 - Brian Hess News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Brian Hess. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Brian Hess Today - Breaking & Trending Today

If Rover Can Make It Here, Perhaps Bald Eagles Can Make It Anywhere - Vimarsana News

If Rover Can Make It Here, Perhaps Bald Eagles Can Make It Anywhere

A white-headed raptor has been preying on smaller birds in Central Park. It’s come a long way since conservationists affixed aluminum bands to its legs four years ago.

No longer endangered, bald eagles still closely watched in Connecticut - Vimarsana News

No longer endangered, bald eagles still closely watched in Connecticut

Connecticut's Department of Energy and Environmental Protection is aware of about 75 nests supporting a population of about 150 to 200 bald eagles.

Governor Wolf: At Least 79 Jobs Coming to Luzerne Co. With Leading Beverage Manufacturer - Vimarsana News

Governor Wolf: At Least 79 Jobs Coming to Luzerne Co. With Leading Beverage Manufacturer

Governor Wolf: At Least 79 Jobs Coming to Luzerne Co. With Leading Beverage Manufacturer.

Governor Wolf: At Least 79 Jobs Coming to Luzerne Co. With Leading Beverage Manufacturer - Vimarsana News

Governor Wolf: At Least 79 Jobs Coming to Luzerne Co. With Leading Beverage Manufacturer

Gov. Wolf announced that Niagara Bottling, LLC, a leading beverage manufacturer in the U.S., is expanding its operations in Pennsylvania and has committed to creating at least 79 jobs at a new production facility in Luzerne County.

Source: pa.gov
MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial - Vimarsana News

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial

MUSC Hollings Cancer Center part of promising phase 2 lymphoma clinical trial MUSC Hollings Cancer Center was one of 28 clinical sites around the world that participated in the LOTIS-2 trial to test the efficacy of Loncastuximab tesirine, a promising new treatment for aggressive B-cell lymphoma. The results of the single-arm, phase 2 trial were published online in May 2021 in Lancet Oncology. Brian Hess, M.D., a Hollings researcher and lymphoma specialist at MUSC Health, was instrumental in bringing the phase 2 trial to Hollings. The manufacturer of Loncastuximab tesirine, ADC Therapeutics S...